squiffy2
06-30-2008, 02:07 AM
Teva Pharmaceutical Industries Ltd. and Antisense Therapeutics Ltd. announced that anti-sense drug, ATL/TV1102, significantly reduced disease activity in patients with relapsing-remitting multiple sclerosis.
The companies noted that their Phase IIa study met its primary endpoint showing a significant reduction by 54.4% in cumulative number of new active lesions in patients taking ATL/TV1102, compared to placebo. In general, ATL/TV1102 was well tolerated..........
For the full report please go to MSRC: MS Research News : Drugs : Further Possible MS Drugs and Treatments (http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1397)
The companies noted that their Phase IIa study met its primary endpoint showing a significant reduction by 54.4% in cumulative number of new active lesions in patients taking ATL/TV1102, compared to placebo. In general, ATL/TV1102 was well tolerated..........
For the full report please go to MSRC: MS Research News : Drugs : Further Possible MS Drugs and Treatments (http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1397)